Advertisement

Tumor-associated trypsin inhibitor in patients with endometrial cancer

Abstract

Aim

The aim of the study was to look for prognostic factors of metastasis or recurrence in patients with endometrial cancer.

Methods

Tumor-associated trypsin inhibitor (TATI) concentrations were measured in serum of 317 patients with endometrial cancer. The assay was done 7 times in each patient, from the moment of diagnosis until the start of follow-up after the completion of treatment. Observation of patients after treatment lasted from 0 to 16 years.

Results

The TATI levels in patients with adverse prognostic factors accumulated in the first 3 assays and then decreased to zero. Mean TATI concentrations were significantly higher in patients with clinically advanced disease (stage IIIB) than patients at stage I (Kruskal-Wallis p = 0.0446). An increase in the concentration by more than 10.6% in the first 3 assays was significantly correlated with disease relapse (Mann-Whitney Z = -6.06653, p = 0.00000) and local or distant recurrence (Mann-Whitney Z = -4.97475, p = 0.000001). A significant increase in the TATI level in the first 3 tests also occurred in patients who died during the study period (Kruskal Wallis p<0.001). In our series of patients with endometrial cancer, TATI proved to be a sensitive indicator of disease recurrence and distant metastasis, with a sensitivity of 84.4% and 75.7%, respectively.

Conclusions

TATI seems to behave as a prognostic factor in certain subgroups of patients with endometrial cancer.

Tumori 2016; 102(5): 527 - 532

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000412

Authors

Barbara Kozakiewicz, Małgorzata Chądzyńska, Ewa Dmoch-Gajzlerska, Małgorzata Stefaniak

Article History

Disclosures

Financial support: No grants or funding have been received for this study.
Conflict of interest: The authors declare that they have no competing interests related to this study.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw - Poland
  • Faculty of Health Sciences Gynecological and Obstetrics Department Medical University, Warsaw - Poland
  • Institute of Psychiatry and Neurology, Warsaw - Poland

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.